Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations

the BRCA1 and BRCA2 genes are as-sociated with an increased risk of breast cancer. Whether women with breast cancer who have inherited mu-tations in these genes have a different outcome after breast conservation therapy than women with “sporadic” cancer is unresolved. Consequently, we compared the outcomes after breast conservation therapy in Ashkenazi women with or without germline muta-tions in BRCA1 and/or BRCA2 (here-after called BRCA). Methods: We stud-ied 305 women of Ashkenazi Jewish descent undergoing breast-conservin